Are peptides really 'some of the greatest supplements'?

What's this video probably claiming?

A Houston-based dermatologist posting under @drobenojong is likely making a broad, enthusiastic endorsement of peptide therapy as a category, framing peptides as superior wellness tools for skin health, recovery, or anti-aging. Given the hashtag mix of #peptidetherapy and #beautyhacks alongside cosmetic dermatology credentials, the video probably positions peptides as accessible, near-miraculous additions to a beauty or longevity routine. The caption's phrasing, 'greatest supplements you can use to support your body,' is deliberately vague, which is a common content strategy that lets viewers project whatever benefit they want onto the claim. Peptides are not legally classified as supplements in the United States. Most bioactive peptides discussed in this category, including GHK-Cu, BPC-157, and CJC-1295, are either research compounds or require a prescription through a licensed compounding pharmacy. Calling them supplements flattens a genuinely complex regulatory and pharmacological picture.

What does the science actually show?

The evidence base for peptides is real but fragmented and highly peptide-specific. GHK-Cu (copper tripeptide-1) has legitimate dermatological research behind it. A 2015 review by Pickart and Margolina in the journal Biomolecules documented its role in stimulating collagen synthesis and wound repair, though most strong data comes from in vitro and animal studies, not large randomized controlled trials in humans. CJC-1295 combined with ipamorelin has been studied for growth hormone secretagogue effects. A 2006 clinical trial by Teichman et al. in the Journal of Clinical Endocrinology and Metabolism showed CJC-1295 increased IGF-1 levels by 28-39% over 28 days at doses of 30-60 mcg/kg, but this was a small trial (n=65) and was not conducted in healthy adults seeking cosmetic outcomes. BPC-157 data is almost entirely preclinical. Sikiric et al. have published extensively in journals like Current Pharmaceutical Design, but human randomized trial data essentially does not exist. The honest answer is that some peptides show promise; very few have cleared the bar of rigorous human evidence.

Where does the social media noise diverge from clinical reality?

The gap between how peptides are discussed online and what the clinical literature supports is significant. TikTok peptide content routinely conflates in vitro results with clinical outcomes, animal model data with human benefit, and anecdotal gym culture with peer-reviewed pharmacology. The phrase 'greatest supplements' implies a safety and efficacy consensus that simply does not exist across this category as a whole. MK-677, for example, is often framed as a safe growth hormone booster. In reality, a 2008 study by Nass et al. in the Journal of Clinical Endocrinology and Metabolism found MK-677 increased fasting glucose and insulin resistance in older adults, raising legitimate metabolic safety concerns. Semax and selank are Russian-developed peptides with almost no English-language RCT data. Physicians presenting these compounds to general audiences without distinguishing between research stages, regulatory status, and individual risk profiles are doing their audience a disservice, regardless of their credentials.

What should you actually know?

Peptides are not a monolith. Lumping GHK-Cu skin creams, injectable BPC-157, and growth hormone secretagogues into one enthusiastic category called 'great supplements' obscures more than it reveals. Some topical peptides with established cosmetic data, like Matrixyl (palmitoyl pentapeptide-4), have decent published evidence for wrinkle reduction. A double-blind study by Lintner et al. published in the International Journal of Cosmetic Science in 2009 showed meaningful collagen density improvements at 3% concentration over 4 months. Injectable peptides are a different conversation entirely, requiring a physician evaluation, compounding pharmacy sourcing, and awareness of regulatory gray zones since the FDA has restricted certain peptides from compounding. If a dermatologist is recommending peptides, the conversation should specify which peptide, what delivery method, what evidence tier supports it, and what the monitoring plan looks like. Broad endorsements without that context are marketing, not medicine.